Cancer treatment in the STI571 era: what will change?
Sawyers
C L
CL
Division of Hematology-Oncology, Department of Medicine, and Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA 90095-1678, USA. csawyers@mednet.ucla.edu
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D019317:Evidence-Based Medicine; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D010879:Piperazines / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D017154:Stromal Cells / Q000187:drug effects / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate